We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.

U.S. markets closed

Johnson & Johnson (JNJ)

NYSE - NYSE Delayed Price. Currency in USD
Visitors trend2W10W9M
147.52-1.27 (-0.85%)
At close: 04:00PM EDT
147.51 -0.01 (-0.01%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Engulfing Line (Bullish)

Engulfing Line (Bullish)

Performance Outlook
Previous Close148.79
Open148.06
Bid147.31 x 800
Ask147.70 x 800
Day's Range147.15 - 149.07
52 Week Range144.95 - 175.97
Volume7,100,178
Avg. Volume7,193,125
Market Cap355.491B
Beta (5Y Monthly)0.53
PE Ratio (TTM)28.42
EPS (TTM)5.19
Earnings DateApr 16, 2024
Forward Dividend & Yield4.76 (3.23%)
Ex-Dividend DateFeb 16, 2024
1y Target Est176.17
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
16% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for JNJ

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Johnson & Johnson
    Analyst Report: Johnson & JohnsonJohnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States.
    Rating
    Fair Value
    Economic Moat
    4 days agoMorningstar
View more
  • Reuters

    UPDATE 1-South Africa recalls J&J's cough syrup sold in six African nations after suspected toxicity

    South Africa's health regulator said on Saturday it is recalling batches of Johnson & Johnson's children's cough syrup after detection of high levels of diethylene glycol. The affected batches were sold in South Africa, Eswatini, Rwanda, Kenya, Tanzania and Nigeria, the statement added. The recall follows a report by the regulator's Nigerian counterpart on Wednesday, which first detected the toxin in a batch of Benylin Paediatric Syrup.

  • Reuters

    South Africa recalls J&J's cough syrup sold in six African nations after suspected toxicity

    South Africa's health regulator said on Saturday it is recalling batches of Johnson & Johnson's children's cough syrup after detection of high levels of diethylene glycol. The affected batches were sold in South Africa, Eswatini, Rwanda, Kenya, Tanzania and Nigeria, the statement added. The recall follows a report by the regulator's Nigerian counterpart on Wednesday, which first detected the toxin in a batch of Benylin Paediatric Syrup.

  • Zacks

    Johnson & Johnson (JNJ) Stock Moves -0.85%: What You Should Know

    The latest trading day saw Johnson & Johnson (JNJ) settling at $147.52, representing a -0.85% change from its previous close.

  • Yahoo Finance Video

    Bank earnings, housing, Trump trial: What to Watch Next Week

    Yahoo Finance anchors Josh Lipton and Jared Blikre queue up the biggest headlines and events for next week, including additional earnings from Big Banks — Goldman Sachs (GS), Charles Schwab (SCHW), Bank of America (BAC), Morgan Stanley (MS) — among other top companies, as well fresh US housing data, the jury selection for Former President Trump's criminal trial, and the Boeing (BA) whistleblowers testimony before Congress. For more expert insight and the latest market action, click here to watch this full episode of Market Domination Overtime. This post was written by Luke Carberry Mogan.

  • Zacks

    3 Quarterly Releases to Watch Next Week

    Earnings season is always an exciting time for investors, with companies finally revealing what's transpired behind closed doors. And concerning next week's docket, these three notable companies are scheduled to report.

  • Zacks

    J&J (JNJ) to Begin Pharma Q1 Earnings Season: What's in Store?

    J&J's (JNJ) Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. Surgical procedure recovery and new products are likely to have driven MedTech sales.

  • Motley Fool

    5 Dividend Kings That Yield More Than Vanguard's Top Value ETF

    Despite a thriving bull market, some Dividend Kings still yield more than the Vanguard Value ETF's 2.4% payout.

  • Reuters

    UPDATE 1-Kenya recalls J&J children's cough syrup over suspected toxicity

    Kenya's drug regulator is recalling a batch of Johnson & Johnson children's cough syrup, it said on Thursday, a day after Nigeria recalled the same batch of medication under the Benylin Paediatric brand. Nigeria's health regulator said laboratory tests on the syrup showed a high level of diethylene glycol, which has been linked to the deaths of dozens of children in Gambia, Uzbekistan and Cameroon since 2022 in one of the world's worst waves of poisoning from oral medication.

  • Reuters

    Kenya recalls J&J children's cough syrup over suspected toxicity

    Kenya's drug regulator is recalling a batch of Johnson & Johnson children's cough syrup, it said on Thursday, a day after Nigeria recalled the same batch of medication under the Benylin Paediatric brand. Nigeria's health regulator said laboratory tests on the syrup showed a high level of diethylene glycol, which has been linked to the deaths of dozens of children in Gambia, Uzbekistan and Cameroon since 2022 in one of the world's worst waves of poisoning from oral medication.

  • Zacks

    Unlocking Q1 Potential of Johnson & Johnson (JNJ): Exploring Wall Street Estimates for Key Metrics

    Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Johnson & Johnson (JNJ), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2024.